Feature|Articles|October 15, 2024
- Pharmaceutical Executive: October 2024
- Volume 44
- Issue 10
Pharmaceutical Executive: October 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Assembly Required: Building Blocks in Biopharmaalmost 2 years ago
Pharma’s Cold Calling: CGT Space at a Critical Crossroadsalmost 2 years ago
‘Selling a Vision’: Today’s Playbook for Startupsalmost 2 years ago
Rafaat Rahmani: Beating the Oddsalmost 2 years ago
AI: A Value Advantage? Maximizing Your Brand Outreachalmost 2 years ago
How to Rally a Team Around Building a New Businessalmost 2 years ago
Trading Quality for Convenience? The New Tech Balancing Actalmost 2 years ago
Amazon Targeting the Transactional in the Pharma MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
5